
Letter to US Congress - suggestions to fix the FDA PRV for neglected diseases
Submission Regarding Bill H.R. 3299: Suggestions to Fix the FDA PRV for Neglected Diseases
Letter requesting support for changes to the Food and Drug Administration (FDA) Priority Review Voucher (PRV) program to ensure that it effectively accomplishes its goal of incentivizing new research and development (R&D) for neglected diseases, and that new neglected diseases products brought to market through the PRV program are made accessible and affordable to those who need them.